JP2022531591A5 - - Google Patents
Info
- Publication number
- JP2022531591A5 JP2022531591A5 JP2021564913A JP2021564913A JP2022531591A5 JP 2022531591 A5 JP2022531591 A5 JP 2022531591A5 JP 2021564913 A JP2021564913 A JP 2021564913A JP 2021564913 A JP2021564913 A JP 2021564913A JP 2022531591 A5 JP2022531591 A5 JP 2022531591A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- pharmaceutical product
- acid sequence
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1906291.8A GB201906291D0 (en) | 2019-05-03 | 2019-05-03 | Treatment and prevention of metabolic diseases |
| GB1906291.8 | 2019-05-03 | ||
| GBGB1906597.8A GB201906597D0 (en) | 2019-05-03 | 2019-05-10 | Treatment and prevention of metabolic diseases |
| GB1906597.8 | 2019-05-10 | ||
| GB2001013.8 | 2020-01-24 | ||
| GBGB2001013.8A GB202001013D0 (en) | 2020-01-24 | 2020-01-24 | Treatment and prevention of metabolic diseases |
| GB2001896.6 | 2020-02-12 | ||
| GBGB2001896.6A GB202001896D0 (en) | 2020-02-12 | 2020-02-12 | Treatment and prevention of metabolic diseases |
| GBGB2002030.1A GB202002030D0 (en) | 2020-02-14 | 2020-02-14 | Treatment and prevention of metabolic diseases |
| GB2002030.1 | 2020-02-14 | ||
| PCT/EP2020/062193 WO2020225147A1 (en) | 2019-05-03 | 2020-05-01 | Treatment and prevention of metabolic diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022531591A JP2022531591A (ja) | 2022-07-07 |
| JP2022531591A5 true JP2022531591A5 (enExample) | 2023-05-09 |
| JP7595028B2 JP7595028B2 (ja) | 2024-12-06 |
Family
ID=73051262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021564913A Active JP7595028B2 (ja) | 2019-05-03 | 2020-05-01 | 代謝性疾患の治療および予防 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11813311B2 (enExample) |
| EP (1) | EP3962936A1 (enExample) |
| JP (1) | JP7595028B2 (enExample) |
| KR (1) | KR20220050087A (enExample) |
| CN (1) | CN114364693A (enExample) |
| AU (1) | AU2020268619B2 (enExample) |
| BR (1) | BR112021021921A2 (enExample) |
| CA (1) | CA3146344A1 (enExample) |
| CL (1) | CL2021002878A1 (enExample) |
| MX (1) | MX2021013356A (enExample) |
| PH (1) | PH12021552763A1 (enExample) |
| TW (1) | TW202108606A (enExample) |
| WO (1) | WO2020225147A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021021921A2 (pt) * | 2019-05-03 | 2021-12-28 | Nat Univ Singapore | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica |
| CA3169779A1 (en) | 2020-02-28 | 2021-09-02 | Andrew Mark Griffin | Kcnt1 inhibitors and methods of use |
| US12400326B2 (en) * | 2020-06-09 | 2025-08-26 | Temasek Life Sicences Laboratory Limited | Automated disease detection system |
| CN113041248A (zh) * | 2021-04-26 | 2021-06-29 | 北京亿药科技有限公司 | Ravoxertinib在制备预防和/或治疗非酒精性脂肪性肝病或肝炎药物中的应用 |
| WO2023006765A1 (en) * | 2021-07-26 | 2023-02-02 | Boehringer Ingelheim International Gmbh | Treatment and prevention of alcoholic liver disease |
| MX2024002611A (es) * | 2021-08-30 | 2024-05-29 | Lassen Therapeutics 1 Inc | Anticuerpos anti-il-11ra. |
| CN114081882B (zh) * | 2021-11-15 | 2023-01-10 | 中国科学院深圳先进技术研究院 | 一种a-fabp蛋白抑制剂及其应用 |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| EP4702047A1 (en) | 2023-04-25 | 2026-03-04 | VVB Bio Pte. Ltd. | Anti il-11 antibody |
| WO2024259282A2 (en) * | 2023-06-15 | 2024-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Interleukin 11 polypeptides and methods of use |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259800T3 (es) | 1990-06-11 | 2006-10-16 | Gilead Sciences, Inc. | Procedimientos de uso de ligandos de acido nucleico. |
| ES2093562B1 (es) | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| US6649192B2 (en) | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| CA2237915A1 (en) | 1998-05-19 | 1999-11-19 | Stephen Shaughnessy | Osteoporosis treatment |
| HK1047109A1 (zh) | 1999-10-15 | 2003-02-07 | University Of Massachusetts | 作为指定基因干预工具的rna干预轨迹基因 |
| EP1311277A4 (en) | 2000-07-18 | 2004-08-25 | Joslin Diabetes Center Inc | METHODS OF FIBROSIS MODULATION |
| WO2003049693A2 (en) * | 2001-12-06 | 2003-06-19 | Wyeth | Method and composition for inducing weight loss |
| US8182814B2 (en) | 2007-10-26 | 2012-05-22 | Csl Limited | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity |
| JP5330398B2 (ja) | 2007-10-26 | 2013-10-30 | シーエスエル、リミテッド | サイトカインムテイン |
| US8518888B2 (en) | 2008-10-14 | 2013-08-27 | Csl Limited | Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R |
| TWI452136B (zh) * | 2010-11-17 | 2014-09-11 | 中外製藥股份有限公司 | A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| CN117843785A (zh) * | 2013-02-07 | 2024-04-09 | Csl有限公司 | Il-11r结合蛋白及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| US20160038589A1 (en) | 2014-08-11 | 2016-02-11 | Ophthotech Corporation | Methods for treating or preventing ophthalmological conditions |
| GB201522186D0 (en) * | 2015-12-16 | 2016-01-27 | Singapore Health Services Pte Ltd And Nat University Of Singapore The | Treatment of fibrosis |
| WO2017141032A1 (en) | 2016-02-15 | 2017-08-24 | Oxford University Innovation Limited | Treatment of fibrotic disorders |
| GB201621431D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore The | Decoy cytokine receptor |
| GB201621439D0 (en) | 2016-12-16 | 2017-02-01 | Singapore Health Services Pte Ltd And Nat Univ Of Singapore | IL-11Ra Antibodies |
| US20180186871A1 (en) * | 2016-12-16 | 2018-07-05 | Singapore Health Services Pte Ltd. | Il-11 antibodies |
| GB201806918D0 (en) | 2018-04-27 | 2018-06-13 | Enleofen Bio Pte Ltd | Combination treatment for eye fibrosis |
| GB201809699D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| GB201809700D0 (en) | 2018-06-13 | 2018-08-01 | Singapore Health Serv Pte Ltd | IL-11 antibodies |
| BR112021021921A2 (pt) * | 2019-05-03 | 2021-12-28 | Nat Univ Singapore | Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica |
-
2020
- 2020-05-01 BR BR112021021921A patent/BR112021021921A2/pt unknown
- 2020-05-01 MX MX2021013356A patent/MX2021013356A/es unknown
- 2020-05-01 US US16/865,259 patent/US11813311B2/en active Active
- 2020-05-01 EP EP20721644.1A patent/EP3962936A1/en active Pending
- 2020-05-01 CA CA3146344A patent/CA3146344A1/en active Pending
- 2020-05-01 AU AU2020268619A patent/AU2020268619B2/en active Active
- 2020-05-01 WO PCT/EP2020/062193 patent/WO2020225147A1/en not_active Ceased
- 2020-05-01 JP JP2021564913A patent/JP7595028B2/ja active Active
- 2020-05-01 CN CN202080049108.3A patent/CN114364693A/zh active Pending
- 2020-05-01 PH PH1/2021/552763A patent/PH12021552763A1/en unknown
- 2020-05-01 KR KR1020217039250A patent/KR20220050087A/ko active Pending
- 2020-05-01 TW TW109114711A patent/TW202108606A/zh unknown
-
2021
- 2021-11-02 CL CL2021002878A patent/CL2021002878A1/es unknown
-
2023
- 2023-10-06 US US18/482,399 patent/US20240156913A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531591A5 (enExample) | ||
| JP2022521591A5 (enExample) | ||
| Amet et al. | Human growth hormone–transferrin fusion protein for oral delivery in hypophysectomized rats | |
| Carteron | Cytokines in rheumatoid arthritis: trials and tribulations | |
| JP5579713B2 (ja) | 高分子の送達増強のための方法および組成物 | |
| US20130078216A1 (en) | Liver targeting molecules | |
| Ubah et al. | Novel, anti-hTNF-α variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development | |
| JP6469012B2 (ja) | インターロイキン−６に対する抗体およびその使用 | |
| BRPI1013341B1 (pt) | Variantes de domínio variável único de imunoglobulina anti-albumina de soro, ligante multiespecífico e composição que compreendem as ditas variantes, bem como ácidos nucleicos e vetor | |
| JP2019526528A5 (enExample) | ||
| EP2999484A1 (en) | Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma | |
| JP6918005B2 (ja) | 細胞内抗原に対して向けられた単一ドメイン抗体 | |
| JP2021505611A5 (enExample) | ||
| CN117003876A (zh) | 一种Anti-CXCR4膜蛋白抗体及其制备方法和应用 | |
| CN120187750A (zh) | 治疗肥胖、糖尿病和肝功能障碍的方法 | |
| JP2023538518A5 (enExample) | ||
| JP2025500288A5 (enExample) | ||
| CN115551542A (zh) | 抗il-33抗体的配制品 | |
| CN113316587A (zh) | 一种双特异性分子及其制备与用途 | |
| JP2024526944A5 (enExample) | ||
| EP2807191B1 (en) | Methods of treating pain by inhibition of vgf activity | |
| CN115666643A (zh) | 用于治疗异位性皮肤炎的抗il-36r抗体 | |
| JP7849919B2 (ja) | ヒトｄｒ３に特異的に結合する抗体及びその用途 | |
| JP7795737B2 (ja) | Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法 | |
| WO2025226312A1 (en) | Fc-null anti-gip antibodies |